Oxford Expression Technologies and Eden Biodesign Sign Co-marketing Agreement
Oxford Expression Technologies (OET) and Eden Biodesign have announced that they have signed a co-marketing agreement. Under the terms of the agreement, OET will offer its customers access to Eden Biodesign’s process development, clinical trial cGMP manufacturing and analytical development services. In return, Eden Biodesign’s customers will have access to OET’s wide range of baculovirus capabilities to meet their individual protein expression requirements.
OET customers will benefit from a smooth transition between optimisation of expression and cGMP production and scale-up and the ability to transfer projects intended for clinical development to Eden Biodesign’s world-class process development, cGMP manufacturing and analytical development services offered from their state-of-the-art EMEA inspected facilities located in Liverpool, UK. Eden Biodesign’s customers will be able to take advantage of OET's experience in troubleshooting baculovirus expression; the use of flashBACTM technology to increase protein yield in difficult to express proteins; and the development of a protocol for optimal expression of their proteins.
Commenting on the alliance, James Bernard, OET’s CEO, said: “This partnership will provide customers with unprecedented choice and flexibility. Through Eden Biodesign, we can offer customers global cGMP-certified scale-up capabilities”
Crawford Brown, CEO of Eden Biodesign, added: “Baculovirus protein expression technology can enable faster, easier and more cost-effective protein production compared with other expression methods. By collaborating with OET, a world leader in the baculovirus field, we can help the increasing number of biotechnology and pharmaceutical companies who are interested in evaluating the performance of their biotherapeutic and vaccine products using this exciting technology to progress rapidly into and through clinical development.”
Other news from the department business & finance
